Background: We evaluated the association between serum levels of insulin-like growth factor-1 (IGF-1), bioavailable testosterone, and surgical Gleason score (GS).
Methods: We analyzed 793 patients who underwent radical prostatectomy and 272 men with negative prostate biopsy. Serum levels of IGF-1 and testosterone were measured before surgery or biopsy.
Results: The mean IGF-1 levels of prostate cancer patients and men with a negative biopsy were 143.8 and 118.9 ng/mL, respectively (P < 0.001). Men with high serum IGF-1 were more likely to have prostate cancer (highest vs lowest quartile, odds ratio [OR] = 3.35; Ptrend < 0.001). However, among men with prostate cancer, the mean IGF-1 levels of those with low (GS ≤ 6), intermediate (GS = 7), and high surgical GS (GS ≥8) were 151.7, 144.1, and 132.9 ng/mL, respectively (P < 0.001). Using quartile analysis, high serum IGF-1 levels were shown to be associated with a low risk of high surgical GS (OR = 0.464; Ptrend = 0.006). Serum bioavailable testosterone concentration was positively correlated with serum IGF-1 level (r = 0.157, P < 0.001). High bioavailable testosterone level was also associated with a low risk of high surgical GS in patients without diabetes mellitus (OR = 0.569; Ptrend = 0.040). Among men with biopsy GS ≤ 3 + 4 (n = 460), upgrading to high surgical GS was more frequent in patients with low IGF-1 level (≤116.0 ng/mL; 9.9%) or low bioavailable testosterone level (≤0.85 ng/mL; 9.3%) than in patients with normal IGF-1 and bioavailable testosterone levels (2.6%; P = 0.004).
Conclusions: Serum levels of IGF-1 and bioavailable testosterone show inverse associations with high surgical GS. This suggests that high-grade prostate cancer develops independently of these two substances.
Keywords: Gleason score; bioavailable testosterone; insulin-like growth factor-1; pathology; prostate cancer.
© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.